[go: up one dir, main page]

NO973667L - Anvendelse av karbazolforbindelser ved behandling av kongestiv hjertefeil - Google Patents

Anvendelse av karbazolforbindelser ved behandling av kongestiv hjertefeil

Info

Publication number
NO973667L
NO973667L NO973667A NO973667A NO973667L NO 973667 L NO973667 L NO 973667L NO 973667 A NO973667 A NO 973667A NO 973667 A NO973667 A NO 973667A NO 973667 L NO973667 L NO 973667L
Authority
NO
Norway
Prior art keywords
treatment
heart failure
congestive heart
carbazole compounds
carvedilol
Prior art date
Application number
NO973667A
Other languages
English (en)
Other versions
NO973667D0 (no
NO314830B1 (no
Inventor
Mary Ann Lukas-Laskey
Jr Robert Ruffolo
Neil Shusterman
Gispert Sponer
Klaus Strein
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973667(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of NO973667L publication Critical patent/NO973667L/no
Publication of NO973667D0 publication Critical patent/NO973667D0/no
Publication of NO314830B1 publication Critical patent/NO314830B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19973667A 1995-02-08 1997-08-08 Anvendelse av carvedilol ved fremstillilng av et medikament for anvendelseved behandling av kongestiv hjertefeil NO314830B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure
PCT/EP1996/000498 WO1996024348A2 (en) 1995-02-08 1996-02-07 Use of carbazole compounds for the treatment of congestive heart failure

Publications (3)

Publication Number Publication Date
NO973667L true NO973667L (no) 1997-08-08
NO973667D0 NO973667D0 (no) 1997-08-08
NO314830B1 NO314830B1 (no) 2003-06-02

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19973667A NO314830B1 (no) 1995-02-08 1997-08-08 Anvendelse av carvedilol ved fremstillilng av et medikament for anvendelseved behandling av kongestiv hjertefeil

Country Status (26)

Country Link
US (6) US5760069A (no)
EP (1) EP0808162B1 (no)
JP (1) JP3546058B2 (no)
KR (1) KR100295940B1 (no)
CN (1) CN1093760C (no)
AT (1) ATE179891T1 (no)
AU (1) AU702106C (no)
BR (1) BR9607111A (no)
CA (1) CA2212548C (no)
CZ (1) CZ292002B6 (no)
DE (1) DE69602424T2 (no)
DK (1) DK0808162T3 (no)
ES (1) ES2134588T3 (no)
FI (1) FI973255A0 (no)
GR (1) GR3030966T3 (no)
HU (1) HUP9900773A3 (no)
NO (1) NO314830B1 (no)
NZ (1) NZ301692A (no)
PL (1) PL321737A1 (no)
RO (1) RO121629B1 (no)
RU (1) RU2197242C2 (no)
SI (1) SI0808162T1 (no)
SK (1) SK106897A3 (no)
UA (1) UA55382C2 (no)
WO (1) WO1996024348A2 (no)
ZA (1) ZA96994B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
CA2267967A1 (en) * 1996-10-09 1998-04-16 Boehringer Mannheim Pharmaceuticals Corp. - Smithkline Beecham Corporati On Limited Partnership No.1 Method for inhibiting stress-activated protein kinases
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
AU751117B2 (en) * 1997-11-12 2002-08-08 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Novel oral dosage form for carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
AU7365900A (en) * 1999-09-08 2001-04-10 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
CA2386954C (en) * 1999-10-29 2011-12-13 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
HRP20030027A2 (en) * 2000-06-28 2004-02-29 Teva Pharma Carvedilol
EP1385509A4 (en) * 2001-04-02 2004-06-30 Smithkline Beecham Corp TREATMENT METHOD
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
AU2002341924A1 (en) * 2001-10-02 2003-04-14 Smithkline Beecham Corporation Novel composition of carvedilol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
EP1474133A4 (en) * 2002-01-15 2006-02-01 Teva Pharma SOLID CRYSTALLINE CARVEDILOL BODIES AND METHODS OF MAKING SAME
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
RU2203063C1 (ru) * 2002-03-12 2003-04-27 Нестерук Владимир Викторович Способ получения твердой лекарственной формы препарата, обладающего диуретическим действием
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
US6951880B2 (en) * 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
CN1678305A (zh) * 2002-06-27 2005-10-05 Sb药物波多黎各公司 卡维地洛磷酸盐和/或其溶剂合物和/或相应组合物和/或治疗方法
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
JP2008506716A (ja) * 2004-07-16 2008-03-06 ニトロメッド インコーポレーティッド 心不全に関連する組成物および方法
EP1781611A1 (en) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) * 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
US20090306081A1 (en) * 2006-05-16 2009-12-10 Letts L Gordon Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
EP2114881A1 (en) * 2007-02-26 2009-11-11 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
AR071810A1 (es) 2008-05-16 2010-07-14 Corthera Inc Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso.
ES2552166T3 (es) 2010-04-12 2015-11-26 Supernus Pharmaceuticals, Inc. Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas
EP2741735A1 (en) 2011-08-12 2014-06-18 Boehringer Ingelheim Vetmedica GmbH Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
JP2019521979A (ja) * 2016-06-13 2019-08-08 アセンディア ファーマシューティカルズ，エルエルシー カルベジロール分散系の非経口徐放送達
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
RU2058144C1 (ru) * 1988-12-15 1996-04-20 Центр по химии лекарственных средств Средство для лечения сердечной недостаточности
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
RU2032685C1 (ru) * 1991-12-16 1995-04-10 Центр по химии лекарственных средств Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
EP0808162B1 (en) 1999-05-12
ATE179891T1 (de) 1999-05-15
PL321737A1 (en) 1997-12-22
RU2197242C2 (ru) 2003-01-27
MX9706042A (es) 1998-06-30
ES2134588T3 (es) 1999-10-01
SK106897A3 (en) 1999-03-12
DE69602424D1 (de) 1999-06-17
EP0808162A2 (en) 1997-11-26
USRE40000E1 (en) 2008-01-08
AU4718196A (en) 1996-08-27
UA55382C2 (uk) 2003-04-15
BR9607111A (pt) 1997-11-04
AU702106C (en) 2005-02-17
RO121629B1 (ro) 2008-01-30
FI973255A7 (fi) 1997-08-07
SI0808162T1 (en) 1999-10-31
NO973667D0 (no) 1997-08-08
US5902821A (en) 1999-05-11
US20030105138A1 (en) 2003-06-05
NZ301692A (en) 2000-09-29
CN1185106A (zh) 1998-06-17
CZ292002B6 (cs) 2003-07-16
JPH10513463A (ja) 1998-12-22
KR19980702085A (ko) 1998-07-15
USRE40707E1 (en) 2009-05-05
HUP9900773A2 (hu) 1999-07-28
ZA96994B (en) 1997-10-27
US5760069A (en) 1998-06-02
CA2212548C (en) 1999-08-24
CN1093760C (zh) 2002-11-06
CA2212548A1 (en) 1996-08-15
DK0808162T3 (da) 1999-11-15
HK1014861A1 (en) 1999-10-08
NO314830B1 (no) 2003-06-02
FI973255A0 (fi) 1997-08-07
CZ246397A3 (cs) 1998-11-11
US20010044455A1 (en) 2001-11-22
AU702106B2 (en) 1999-02-11
JP3546058B2 (ja) 2004-07-21
WO1996024348A3 (en) 1996-10-03
GR3030966T3 (en) 1999-11-30
KR100295940B1 (ko) 2001-08-07
HUP9900773A3 (en) 2000-04-28
WO1996024348A2 (en) 1996-08-15
DE69602424T2 (de) 1999-10-07

Similar Documents

Publication Publication Date Title
NO973667L (no) Anvendelse av karbazolforbindelser ved behandling av kongestiv hjertefeil
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
DK0490772T3 (da) 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem
ATE282418T1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
WO2002008219A3 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
SG49692A1 (en) Process for the production of a pharmaceutical agent for oral or topical administration in the treatment of leishmaniasis
NO964348L (no) CCK- eller gastrin-modulerende 5-hetrocykliske-1,5-benzodiazepiner
ES2158996T3 (es) Agonistas beta3 adrenergicos selectivos.
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
NZ308260A (en) Use of 5-(substituted biphenyl)-tetrazole derivatives to treat multiple system organ failure
EE9700231A (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
NO173137C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser
ATE167399T1 (de) Verwendung von sulfasalazin und/oder dessen aktiven metaboliten zur herstellung eines arzneimittels zur behandlung von venöser insuffizienz und venösen ulcera
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
FR2433516A1 (fr) Pyridoxines, leur preparation et leurs utilisations therapeutiques
DK93485D0 (da) Farmaceutisk praeparat til behandling af hypertension og thromboemboliske sygdomme
FR2401922A1 (fr) Picolylamides d'acides 4-hydroxy-isophtaliques substitues, leur preparation et leurs utilisations therapeutiques
NO952234L (no) Transdermalt administreringsystem inneholdende acetylsalisylsyre for antitromboseterapi og forebygging av kreft
NO308195B1 (no) Anvendelse av benzydamin til fremstilling av et legemiddel ved behandling av patologiske tilstander forÕrsaket av TNF
DE69528068D1 (de) Conagenine zur prävention und behandlung von diarrhöe
ES2120251T3 (es) 3-alcoxicarbonil-tiadiazinonas cardioactivas.
ES2118451T3 (es) Preparado medicamentoso oral que contiene diclofenaco sodico y un acido organico.
PT1001943E (pt) Derivados de poli-hidroxialquilpirazinas sua preparacao e medicamentos que os contem
IL151878A0 (en) Pharmaceutical compositions containing t3
RU92001939A (ru) Способ лечения псориаза

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees